Important Program Updates to myAbbVie Assist Patient Assistance program (PAP) for HUMIRA® (adalimumab)

• A biosimilar is defined as a medicine that is different from the original but has no clinically meaningful differences in terms of safety, purity, or potency. Over the past few years, several biosimilar options for HUMIRA have gained FDA approval and have been released for patient use. Since biosimilars are often lower cost, many insurance plans now prefer biosimilars instead of HUMIRA.
• Click here for a listing of FDA-approved biosimilars and website information.  Visit the biosimilar’s official website or reach out to their support team for details about their product and available benefits.

No, there are no immediate impacts to a patient’s current enrollment or ability to receive their medication. Patients currently enrolled may remain in the program until their enrollment end date. 

AbbVie understands that treatment decisions are made between a patient and their provider. Accordingly, AbbVie does not help identify or provide alternative treatment options for patients.

• If you have insurance, check with your insurance provider to understand what other treatment options are covered through your plan.
• Contact your healthcare provider to discuss what treatment options are right for you and begin next steps towards an alternate treatment plan.
• For a list of FDA-approved biosimilars and website information, please click here.

• Humira will be phased out of the myAbbVie Assist PAP and no longer available for new patients. Existing patients will be unable to renew their enrollment.
• If you are doing well on HUMIRA, an adalimumab biosimilar may be an option to support continued therapy. Many biosimilars have a patient assistance program for patients with affordability concerns. Please review the product information for approved indications and dosing, as well as PAP program availability. For your information, please click here for a listing of FDA-approved biosimilars and website information.
• If a new therapeutic plan would better meet your goals, other AbbVie treatment options offered through myAbbVie Assist such as SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) may be available. Please see the product labeling for approved indication and dosing.
• Discuss with your healthcare provider about what option is best for you.
  

• Biosimilars may have their own patient assistance programs. For your information, please click here for a listing of FDA-approved biosimilars and website information. To see details about their eligibility requirements and benefits, please visit the biosimilar’s official website or reach out to their support team.

AbbVie supports the entry of biosimilars that have been shown, with robust evidence, including clinical trials, to be as safe and efficacious as originator biologic medicines. Please see our position through the following link: https://news.abbvie.com/2015-17-20-Committed-to-Biologic-Innovation  

For further information, please call 1-800-222-6885, available Monday through Friday from 7am-7pm CST, to speak with a Patient Assistance Counselor.